69$/KG
Product Detailed Description
Liposomal Calcium Citrate 80% is a premium-grade dietary supplement ingredient delivering calcium citrate in an advanced liposomal delivery system. Calcium citrate (CAS 813-94-5 for anhydrous; CAS 5785-44-4 for tetrahydrate) is the calcium salt of citric acid, chemically designated as 2-hydroxy-1,2,3-propanetricarboxylic acid calcium salt (2:3). It occurs as a white, odorless, crystalline powder that is soluble in water and contains approximately 21% elemental calcium.
Calcium is the most abundant mineral in the human body, with approximately 99% stored in bones and teeth as hydroxyapatite complexes that provide strength and structure. The remaining 1% of "non-bone calcium" plays crucial roles in muscle contraction, nerve impulse transmission, blood clotting, and hormone secretion. Calcium citrate is preferred over calcium carbonate in several clinical situations, including chronic hypoparathyroidism, osteoporosis, hypochlorhydria (low gastric acid production), and bariatric surgery, because it does not depend on stomach acid for absorption. However, conventional calcium citrate still faces absorption limitations, and the rapid postprandial spike in serum calcium levels associated with traditional calcium supplements can lead to inefficient utilization.
Conventional calcium citrate already offers superior bioavailability compared to calcium carbonate. A meta-analysis of 15 studies demonstrated that calcium citrate is absorbed approximately 22–27% better than calcium carbonate, regardless of whether it is taken on an empty stomach or with meals. However, calcium absorption relies on tightly regulated intestinal transport systems, and increasing the administered dose does not proportionally enhance absorption efficiency but may instead lead to reduced fractional absorption and increased excretion.
Liposomal encapsulation provides four critical advantages:
1. Enhanced Bioavailability — A randomized crossover human absorption study demonstrated that solid-state liposomal calcium achieved a 1.56-fold increase in systemic calcium exposure compared to non-liposomal calcium. The AUC was 2.94 mg·h/dL for the liposomal group versus 1.88 mg·h/dL for the non-liposomal group.
2. Improved Absorption Kinetics — Liposomal calcium significantly increased blood calcium levels at early time points (1–2 h; p < 0.05) and maintained elevated levels up to 8 hours post-administration, indicating both a faster onset and a more sustained duration of action.
3. Lymphatic Absorption Pathway — By migrating directly into the lymphatic system, liposomal calcium avoids liver first-pass metabolism, elevating serum calcium safely and efficiently. This delivery route bypasses the rapid postprandial spike in serum calcium levels that can occur with traditional calcium supplements.
4. Reduced Gastrointestinal Side Effects — Liposomal encapsulation minimizes direct contact between calcium and the gastrointestinal mucosa, reducing the risk of the constipation and bloating frequently associated with conventional calcium supplements.
High Purity — Standardized to ≥80% calcium citrate, with elemental calcium content of ≥20.0%.
Liposomal Enhancement — Phospholipid bilayer encapsulation achieves a 1.56-fold increase in systemic calcium exposure compared to non-liposomal calcium.
Superior Bioavailability — Calcium citrate is absorbed approximately 22–27% better than calcium carbonate, and liposomal encapsulation further enhances this advantage through lymphatic absorption pathways.
Stomach-Acid Independent — Calcium citrate is absorbed equally well with or without food, making it ideal for individuals with low stomach acid, those taking proton pump inhibitors, and older adults.
Osteoporosis Prevention — Clinical studies have demonstrated that calcium citrate supplementation (400 mg of calcium twice daily) averted bone loss and stabilized bone density in the spine through parathyroid suppression and inhibition of bone resorption.
Reduced Kidney Stone Risk — Calcium citrate, in contrast to other calcium salts, reduces the risk of kidney stone formation.
Enhanced Stability — Liposomal formulations exhibit remarkable physicochemical stability over a 6-month storage period at 4°C and 25°C, with retention rates of >98% for calcium.
Water-Dispersible — Suitable for capsules, tablets, powder drink mixes, and functional beverages.
Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.
| Application | Recommended Usage | Notes |
|---|---|---|
| Capsules / Tablets | 200–400 mg elemental calcium per serving | 2–3 capsules daily, with or without food |
| Functional Beverages | 100–250 mg per 250 mL | Water-dispersible; suitable for RTD formats |
| Powdered Drink Mixes | 500–1,000 mg per sachet | Blend with vitamin D3 and K2 for synergistic bone support |
| Bone Health Formulas | 500–1,200 mg per serving | Often combined with vitamin D, magnesium, and vitamin K2 |
| Hypochlorhydria Formulas | 500–1,000 mg per serving | Preferred form for individuals with low gastric acid production |
According to the International Osteoporosis Foundation, the recommended daily calcium intake for both women and men aged 19 to 50 years is 1,000 mg. This increases to 1,200 mg from the age of 51 in women, and after 70 in men. Approximately 20–30% of ingested dietary calcium is absorbed by the gut. Calcium citrate supplements typically provide 200–400 mg of elemental calcium per serving, and because calcium citrate is only 21% calcium, more tablets may be needed to meet daily requirements compared to calcium carbonate. The Tolerable Upper Intake Level (UL) for calcium is 2,000–2,500 mg per day for adults. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability.
Stock Orders: 3–5 business days after payment confirmation.
Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.
Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.
Coverage: Worldwide shipping, including remote areas.
Calcium Citrate Encyclopedia — Scientific Background
Calcium citrate (CAS 813-94-5 for anhydrous; CAS 5785-44-4 for tetrahydrate) is the calcium salt of citric acid, chemically designated as 2-hydroxy-1,2,3-propanetricarboxylic acid calcium salt (2:3). It occurs as a white, odorless, crystalline powder that is soluble in water. The anhydrous form has a molecular formula of C₁₂H₁₀Ca₃O₁₄ and a molecular weight of 498.43 g/mol, while the tetrahydrate form has a molecular weight of 570.49 g/mol. Calcium citrate contains approximately 21% elemental calcium and is widely used as a dietary supplement, nutrient, sequestrant, buffer, and firming agent in food and pharmaceutical applications.
Intestinal calcium absorption occurs through two distinct mechanisms:
Transcellular Absorption — An active, energy-dependent process that takes place primarily in the duodenum. It is dependent on the concentration of calcium-binding proteins and is rapidly saturable. This pathway requires active vitamin D and is responsible for most calcium absorption in individuals with low to normal calcium intake.
Paracellular Absorption — A passive, energy-independent process that occurs throughout the intestine. It is independent of calcium concentration in the gut lumen and is not rapidly saturable. This pathway is not vitamin D dependent and accounts for most calcium absorption in individuals with high calcium intake.
Calcium citrate is absorbed via the paracellular pathway, which does not require stomach acid for dissolution. This is why calcium citrate is absorbed equally well with or without food and is the preferred form for individuals with hypochlorhydria or those taking acid-reducing medications.
Calcium citrate increases plasma calcium levels, which reduces calcium flux from osteocyte activity by reducing the secretion of parathyroid hormone (PTH). Calcium stimulates a G-protein coupled calcium receptor on the surface of parathyroid cells, and the reduction in calcium flux increases the amount of calcium deposited in bone, resulting in increased bone mineral density.
Clinical studies have demonstrated that calcium citrate supplementation (400 mg of calcium twice daily) averted bone loss and stabilized bone density in the spine. This bone-sparing action is attributed to the inhibition of bone resorption from parathyroid suppression.
The citrate component of calcium citrate also contributes to bone health by neutralizing the acid load caused by high protein intake or low intake of alkalizing foods. Citrate is an essential player in maintaining acid-base balance and in driving the mineralization process.
| Property | Calcium Citrate | Calcium Carbonate |
|---|---|---|
| Elemental Calcium | ~21% | ~40% |
| Absorption | 22–27% better absorption than carbonate | Requires gastric acid for optimal absorption |
| Food Dependency | Absorbed equally well with or without food | Should be taken with meals |
| Stomach Acid | Not dependent on gastric acid | Requires stomach acid |
| Kidney Stone Risk | Reduces risk of kidney stone formation | No demonstrated protective effect |
| Best For | Older adults, those on PPIs, hypochlorhydria | Younger adults with normal gastric acid |
Liposomal encapsulation of calcium citrate provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the calcium citrate complex, forming a protective shell that enhances absorption and enables lymphatic delivery. This delivery system:
Protects calcium from premature interaction with gastric contents and dietary inhibitors
Enhances intestinal absorption through both paracellular and lymphatic pathways
Provides sustained release with prolonged blood calcium elevation
Minimizes direct contact between calcium and the gastrointestinal mucosa
By migrating directly into the lymphatic system, liposomal calcium avoids liver first-pass metabolism, elevating serum calcium safely and efficiently. Liposomal formulations exhibit remarkable physicochemical stability over a 6-month storage period at 4°C and 25°C, with retention rates of >98% for calcium.
A randomized crossover human absorption study evaluated the effects of solid-state liposomal calcium on blood calcium response and absorption efficiency compared with non-liposomal calcium. Subjects received a single dose of either solid-state liposomal calcium or non-liposomal calcium, and blood calcium levels were measured over an 8-hour period. Solid-state liposomal calcium significantly increased blood calcium levels at early time points (1–2 h; p < 0.05) and maintained elevated levels up to 8 h post-administration. The AUC was higher in the liposomal group (2.94 mg·h/dL) compared to the non-liposomal group (1.88 mg·h/dL), representing a 1.56-fold increase in systemic calcium exposure.
Clinical studies have demonstrated that calcium citrate supplementation (400 mg of calcium twice daily) averted bone loss and stabilized bone density in the spine. This bone-sparing action was attributed to the inhibition of bone resorption from parathyroid suppression. Studies from the University of Texas Southwestern Medical Center have shown that calcium citrate is absorbed better than calcium carbonate and prevents osteoporosis in women who are in the early stages of postmenopause.
Calcium citrate is preferred in several clinical situations where calcium carbonate is less effective. These include chronic hypoparathyroidism, hypochlorhydria (low gastric acid production), and bariatric surgery, where nutrient absorption is impaired. Calcium citrate ensures adequate calcium intake in patients with impaired absorption because it does not depend on stomach acid for absorption.
Calcium citrate is generally well tolerated. The most common side effects are gastrointestinal, including constipation, bloating, and gas, though these are less frequent with calcium citrate than with calcium carbonate. The Tolerable Upper Intake Level (UL) for calcium is 2,000–2,500 mg per day for adults. Calcium citrate has never been shown to increase the risk of kidney stones the way calcium carbonate can; in fact, the citrate component helps reduce the risk of kidney stone formation.
Calcium citrate is Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration under 21 CFR 184.1195 and is permitted in food with no limitations other than current good manufacturing practice. It is also permitted by the FDA in infant formula. In the European Union, calcium citrate is authorized as a food additive (E333(iii)) under EU regulation EC 1170/2009. Calcium citrate is widely commercialized as a dietary supplement ingredient and pharmaceutical agent. Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.
This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.
69$/KG
RELATED
RELATED
RELATED
RELATED
This website uses cookies to ensure you get the best experience on our website.
Español
Français
Deutsch
日本語
한국어
Phone
Comment
（0）